The revolutionary BiVACOR heart device was moved to Phase 2 of FDA trials after success in five human patients.

Ex-Takeda VP Tauhid Ali, Ph.D., with broad leadership and drug development experience becomes Board DirectorSeasoned regulatory strategist Darren Rubin becomes VP, Amalive, heading development of the ...

(NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare ...

We believe this agreement is in the best interests of Fortrea and all our stakeholders. Erin brings valuable experience to the Board, and we look forward to working with her.” “ We appreciate the ...

Neurofilament light (NFL) is a powerful and sensitive biomarker for tracking neuronal health and disease progression.

Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But without US foreign aid dollars, its delivery to millions worldwide is under ...

ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare.

Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ETCompany ParticipantsChris Lewis - Vice President, ...

Modulight Corporation | Company Release | February 21, 2025 at 13:00:00 EET This release is a summary of Modulight's financial statements bulletin 2024. The whole report is attached to this stock exch ...

The firm plans to build on its organ and tissue modeling technology to develop more sophisticated tests, including full-body digital twins.

Integrating advanced data analytics into clinical practice to improve patient care Amsterdam, The Netherlands and Cambridge, MA ? Royal Philips , a global leader in health technology, and Mass General ...

The Allspring Growth Fund underperformed the Russell 3000 Growth Index during the quarter that ended December 31, 2024. Click ...